Q2 2026 revenue grew 18% year-over-year to $10.9M, with strong gains in navigation and capital equipment segments, but a decline in biologics due to a non-recurring order. Strategic focus shifted to clinical support, CAL facility ramp, and technology development, with 2026 revenue guidance set at…
Q2 2026 revenue grew 18% year-over-year to $10.9M, driven by strong neurosurgery navigation and IRRAflow sales, while Biologics and Drug Delivery declined due to a non-recurring order. Strategic focus shifted to clinical support, CAL facility expansion, and technology development, with 2026 revenue…
Revenue reached $37.0 million in 2025 with a 63% gross margin, driven by growth in biologics, navigation, laser therapy, and neurocritical care. The company targets $200m annual revenue from existing markets and $300m from new cell and gene therapy markets, supported by 60+ pharma partners and rece…
RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. NASDAQ:CLPT (the "Company"), a global device, cell, and gene…
CLPT (ClearPoint Neuro Inc.) is set to announce its Q2'26 results on August 03, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q2'26, revenue estimate is 12.73 million USD with EPS (earnings per share) anticipated at (0.29) USD. Learn more details…
